India, July 30 -- The administration of US President Donald Trump has officially confirmed plans to sunset a temporary federal subsidy programme designed to control prescription drug premiums under Medicare Part D. The Centres for Medicare & Medicaid Services announced that the premium stabilisation demonstration will conclude at the end of 2026, marking a significant policy shift in federal healthcare oversight.

Federal health officials defended the decision by asserting that private insurance sponsors have acquired sufficient operational experience under redesigned benefit structures to price coverage accurately without external fiscal intervention. The move affects millions of older adults enrolled in standalone drug plans across the ...